Is CASI Pharmaceuticals Inc (CASI) a Stock to Watch After Gaining 31.72% This Week?

CASI Pharmaceuticals Inc (CASI) stock has risen 31.72% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

CASI Pharmaceuticals Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on CASI!

See Full CASI Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With CASI Stock Today?

CASI Pharmaceuticals Inc (CASI) stock is trading at $2.99 as of 3:20 PM on Thursday, Jun 1, an increase of $0.17, or 6.03% from the previous closing price of $2.82. The stock has traded between $2.91 and $3.09 so far today. Volume today is 16,142 compared to average volume of 15,821. To screen for more stocks like CASI Pharmaceuticals Inc click here.

More About CASI Pharmaceuticals Inc

CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing innovative therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA. The company primarily operates in the United States, Canada, China and other parts of the world. Click Here to get the full Stock Report for CASI Pharmaceuticals Inc stock.